Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
Actinium Pharmaceuticals develops targeted radiotherapies for cancer using its Antibody Radiation Conjugates platform and alpha-emitting radioisotopes. Company updates commonly focus on ATNM-400, an Actinium-225 antibody radioconjugate studied in solid tumor models including prostate, lung, and breast cancer, and Actimab-A, or lintuzumab-Ac225, an Actinium-225 therapy targeting CD33 in acute myeloid leukemia.
Additional announcements describe radiochemistry work such as chelator-to-antibody ratio optimization, preclinical data presented at oncology and nuclear medicine meetings, and the company's broader radiotherapy platform across solid tumors, hematologic malignancies, and conditioning for cellular therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Actinium Pharmaceuticals presented groundbreaking preclinical data on HER3-targeted radiotherapy at the AACR 2023 Annual Meeting, reporting a significant reduction in tumor volume (p<0.0001) for ovarian cancer when conjugated to Actinium-225 or Lutetium-177, outperforming bevacizumab.
The HER3 target is frequently overexpressed in various solid tumors and linked to poor survival rates. The results indicated effective target engagement and cytotoxic activity in preclinical models for both ovarian and colorectal cancers.
Actinium aims to address high unmet medical needs, highlighting the potential for broad application in different oncology indications. The data showcases Actinium's innovative approach, reaffirming its commitment to developing efficient targeted therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) recently showcased promising data on Actimab-A, a targeted radiotherapy, at the AACR 2023 Annual Meeting in Orlando, Florida. The data highlights Actimab-A's ability to effectively deplete myeloid derived suppressor cells (MDSCs), which are known to inhibit immune responses in various cancers. Key findings include:
- Actimab-A demonstrated superior effectiveness in depleting MDSCs compared to other treatments like Mylotarg.
- Data supported its potential as a backbone therapy to enhance the efficacy of immunotherapies across multiple solid tumor types.
- The treatment showed promise in boosting the antitumor activity of immunotherapies, including checkpoint inhibitors.
Actinium is actively pursuing further development of Actimab-A, aiming to leverage its capabilities in combination therapies.